Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + SOX + nab-paclitaxel as neoadjuvant therapy for resectable locally advanced gastric/GEJ adenocarcinoma
ChiCTR2400082697Phase 2Recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Apr 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, tegafur, oxaliplatin and paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Pathological complete response. Started Apr 2024; status: recruiting.
02
Drugs
adebrelimabtegafuroxaliplatinpaclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400082697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082697.